Kevin K. Lin

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

Christian A. Ross, Hu Li, C. Scott, 2020, bioRxiv.

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

U. Reineke, J. Ungewiss, T. Harding, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.

Juswinder Singh, M. Nacht, M. Raponi, 2011 .

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

G. Shapiro, T. Yap, R. Jeselsohn, 2022, JCO precision oncology.

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

U. Reineke, J. Ungewiss, T. Harding, 2022, European Journal of Nuclear Medicine and Molecular Imaging.